Corvus Pharmaceuticals (CRVS) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
Corvus Pharmaceuticals (CRVS) has outperformed Verastem (VSTM) over the past year, gaining 35.2% versus a loss of 6.2%. Over five years, CRVS leads with a +113.0% price change compared with -71.7% for VSTM. Corvus Pharmaceuticals is the larger company by market cap ($800.8 million vs $783.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVS | VSTM |
|---|---|---|
| Share price | $9.52 | $8.65 |
| Market cap | $800.83M | $783.37M |
| 1-day change | -3.35% | -6.28% |
| YTD return | +23.64% | +12.05% |
| 1-year return | +35.23% | -6.18% |
| 5-year return | +112.98% | -71.73% |
| EPS (TTM) | $-0.62 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $30.91M |
| Revenue growth (YoY) | — | +209.14% |
| Net income (latest FY) | $-15.28M | $-209.47M |
| Operating margin | — | -550.33% |
| Net margin | — | -677.59% |
| 52-week high | $26.95 | $10.82 |
| 52-week low | $6.39 | $3.43 |
| Distance from 52-week high | -64.68% | -20.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +248.11% | +90.06% |
| Average volume | 976.81K | 3.05M |
| Shares outstanding | 84.12M | 90.56M |
| Employees | 37 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRVS has outperformed VSTM by 41.4 percentage points over the past year.
About Corvus Pharmaceuticals
CRVS stock →Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
CRVS vs VSTM FAQ
Which is bigger, Corvus Pharmaceuticals or Verastem?
Corvus Pharmaceuticals (CRVS) is larger, with a market capitalization of $800.83M compared with $783.37M for Verastem (VSTM).
Which stock has performed better over the past year, CRVS or VSTM?
CRVS returned +35.23% over the past 12 months, compared with -6.18% for VSTM (price return, excluding dividends). Past performance does not predict future results.
Are Corvus Pharmaceuticals and Verastem in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.